A Phase 3 interventional study of Tislelizumab and Placebo in Recurrent or Metastatic Nasopharyngeal Cancer, sponsored by BeiGene. Completed at 37 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Nasopharyngeal Neoplasms with a site in China — 22 open to participants now, 30 under way, 6 of them phase 3. Nasopharyngeal Neoplasms · China.
Among the 83 studies in Nasopharyngeal Neoplasms with a site in China, this one is the 21st largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2019, is one of 11 in phase 3, and was the 52nd registered.
226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.
Browse Nasopharyngeal Neoplasms studies →22 of the 83 studies in Nasopharyngeal Neoplasms with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–65
Sun Yat-sen University · Sites in China
Ages 18–70
Ruijin Hospital · Sites in China
Ages 18+
Jiangxi Provincial Cancer Hospital · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 42 · Phase 3 13 · Phase 4 1
First in 1995; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 60 across 178 interventional studies indexed under Nasopharyngeal Neoplasms.
Median enrollment 100 across the 73 interventional studies, 836 across the 10 observational. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 1 study filed under Nasopharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Nasopharyngeal Neoplasms with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05587374Phase 3Sun Yat-sen UniversityCadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) | 2027-08-01 |
| NCT06688175The First Affiliated Hospital of Xiamen UniversityIMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma | 2026-12-31 |
| NCT07326358Ruijin HospitalAI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study | 2026-12-31 |
| NCT07552545Sun Yat-sen UniversityFull-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral Surgery | 2027-05-31 |
| NCT06802835Sun Yat-sen UniversityEGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 83 studies in Nasopharyngeal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was designed to compare the efficacy and safety of tislelizumab (BGB-A317) combined with gemcitabine plus cisplatin versus placebo combined with gemcitabine plus cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal cancer.
226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.
This study's enrollment of 263 is above the median of 60 across 178 interventional studies indexed under Nasopharyngeal Neoplasms.
Browse Nasopharyngeal Neoplasms studies →BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Compared within Nasopharyngeal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Received any approved systemic anticancer therapy, including hormonal therapy, within 28 days prior to initiation of study treatment. The following exception is allowed:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tislelizumab 200 mg intravenously (IV) once every 3 weeks (Q3W), gemcitabine 1 g/m\^2 IV on days 1 and 8 of each 21-day cycle and cisplatin 80 mg/m\^2 IV on day 1 of each cycle for 4 to 6 treatment cycles. Participants may have received treatment for longer at the Investigator's discretion until disease progression. Participants with confirmed disease progression may have continued to receive tislelizumab monotherapy.
Drug: Tislelizumab · Drug: Gemcitabine · Drug: Cisplatin
Participants received placebo IV once every 3 weeks, gemcitabine 1 g/m\^2 IV on days 1 and 8 of each 21-day cycle and cisplatin 80 mg/m\^2 IV on day 1 of each cycle for 4 to 6 treatment cycles. Participants may have received treatment for longer at the Investigator's discretion until disease progression. Participants with confirmed disease progression may have crossed over to receive tislelizumab 200 mg IV Q3W monotherapy.
Drug: Placebo · Drug: Gemcitabine · Drug: Cisplatin
200 mg intravenously (IV) once every 3 weeks (Q3W)
Also known as: BGB-A317
Placebo to match tislelizumab (administered intravenously Q3W)
1 gram per square meter of body surface area (g/m\^2) on Day 1 and day 8 of each cycle, administered as an IV infusion within 30 minutes, for 4 to 6 cycles
80 milligrams per square meter of body surface area (mg/m\^2) on Day 1 of each cycle, administered as an IV infusion for over 4 hours if possible or with proper infusion time based on local clinical guidelines or clinical practice and according to the treating physician's clinical judgment, for 4 to 6 cycles.
Progression-free Survival as Assessed by the Independent Review Committee (IRC)
Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Kaplan-Meier methodology was used to estimate the median PFS.
Time frame: Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)
Overall Response Rate (ORR) as Assessed by the IRC
Defined as the percentage of participants who had complete response or partial response as assessed by the IRC per RECIST v1.1 in all randomized participants with measurable disease at Baseline.
Time frame: Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)
Duration of Response (DOR) as Assessed by the IRC
Defined as the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever occurred first, as assessed by the IRC per RECIST v1.1 in all randomized participants with documented objective responses.
Time frame: Through the study interim data analysis cutoff date of March 26th, 2021 (maximum time on study follow-up was 23 months)
Overall Survival (OS) as Assessed by the IRC
Defined as the time from the date of randomization to the date of death due to any cause.
Time frame: Through study completion data cut-off date of December 8th, 2023 or last available date showing participants alive (maximum time on study follow-up was 53 months)
PFS as Assessed by the Investigator
Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the investigator per RECIST v1.1.
Time frame: Through the interim analysis data cut-off date of March 26th, 2021 (up to approximately 23 months)
Progression-free Survival After Next Line of Treatment (PFS2) as Assessed by the Investigator
Defined as the time from randomization to second/subsequent disease progression after initiation of new anticancer therapy, or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Through the study completion data cut-off date of December 8th, 2023 (maximum time on study follow-up was 53 months)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 (Each cycle is 21 days)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck-351 (EORTC QLQ-H&N35) Index Score
The QLQ-H\&N35 consists of thirty-five questions that are associated with eighteen symptom scales (pain, swallowing, senses, speech, social eating, social contact, sexuality, problem with teeth, problem opening mouth, dry mouth, problem with sense smell, cough, felt ill, pain med, nutritional supplements, feeding tube, weight loss and weight gain).. Raw scores are transformed into a 0 to 100 scale via linear transformation. The index score is calculated as an average of the 18 symptom scales. A negative change from baseline score indicates improvement in symptoms.
Time frame: Baseline to Cycle 6 (Each cycle is 21 days)
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, vital signs, electrocardiograms (ECGs), and physical examinations (PEs ), graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. For Arm B, only adverse events reported prior to participants crossing over to receive tislelizumab monotherapy are included.
Time frame: From first dose to 30 days after last dose or new anticancer therapy, or until Dec 8, 2023 data cut-off; max treatment duration: 231 weeks (Arm A), 202 weeks (Arm B).
Participants were enrolled in multiple study centers in China, Thailand, and Taiwan. The first participant was consented on March 27th 2019, and the last participant completed on December 8th 2023.
| Milestone | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Started | 131 | 132 |
| Treated | 131 | 132 |
| Crossed over to tislelizumab | 0 | 70 |
| Completed | 0 | 0 |
| Not completed | 131 | 132 |
| Withdrew: Death | 57 | 66 |
| Withdrew: Study concluded by sponsor | 51 | 41 |
| Withdrew: Withdrawal by subject | 15 | 20 |
| Withdrew: Lost to follow-up | 7 | 5 |
| Withdrew: Miscellaneous | 1 | 0 |
Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Kaplan-Meier methodology was used to estimate the median PFS.
| Months | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Progression-free Survival as Assessed by the Independent Review Committee (IRC) | 9.2 (7.6 to 10.1) | 7.4 (5.6 to 7.5) |
Defined as the percentage of participants who had complete response or partial response as assessed by the IRC per RECIST v1.1 in all randomized participants with measurable disease at Baseline.
| percentage of participants | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Overall Response Rate (ORR) as Assessed by the IRC | 69.5 (60.8 to 77.2) | 55.3 (46.4 to 64.0) |
Defined as the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever occurred first, as assessed by the IRC per RECIST v1.1 in all randomized participants with documented objective responses.
| months | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Duration of Response (DOR) as Assessed by the IRC | 8.5 (6.5 to NA) | 6.1 (4.7 to 6.2) |
Defined as the time from the date of randomization to the date of death due to any cause.
| Months | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Overall Survival (OS) as Assessed by the IRC | 45.3 (33.4 to NA) | 31.8 (25.0 to NA) |
Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the investigator per RECIST v1.1.
| months | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| PFS as Assessed by the Investigator | 9.8 (7.8 to 11.9) | 7.6 (6.6 to 7.8) |
Defined as the time from randomization to second/subsequent disease progression after initiation of new anticancer therapy, or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
| months | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Progression-free Survival After Next Line of Treatment (PFS2) as Assessed by the Investigator | 45.3 (31.5 to NA) | 20.5 (13.9 to 27.2) |
Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
| score on a scale | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status | 0.2 ± 25.18 | -0.1 ± 20.72 |
The QLQ-H\&N35 consists of thirty-five questions that are associated with eighteen symptom scales (pain, swallowing, senses, speech, social eating, social contact, sexuality, problem with teeth, problem opening mouth, dry mouth, problem with sense smell, cough, felt ill, pain med, nutritional supplements, feeding tube, weight loss and weight gain).. Raw scores are transformed into a 0 to 100 scale via linear transformation. The index score is calculated as an average of the 18 symptom scales. A negative change from baseline score indicates improvement in symptoms.
| score on a scale | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck-351 (EORTC QLQ-H&N35) Index Score | -0.3 ± 6.40 | -0.3 ± 7.17 |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory tests, vital signs, electrocardiograms (ECGs), and physical examinations (PEs ), graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. For Arm B, only adverse events reported prior to participants crossing over to receive tislelizumab monotherapy are included.
| Participants | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin |
|---|---|---|
| TEAEs | 133 | 129 |
| SAEs | 47 | 46 |
Collected over From first dose to 30 days after the last dose or initiation of a new anticancer therapy, maximum duration of treatment was 231 weeks in Arm A and 202 weeks in Arm B.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Tislelizumab + Gemcitabine + Cisplatin | 57/133 (42.9%) | 47/133 (35.3%) | 133/133 (100%) |
| Arm B: Placebo + Gemcitabine + Cisplatin | 31/130 (23.8%) | 46/130 (35.4%) | 129/130 (99.2%) |
| Post Crossover Tislelizumab | 35/70 (50%) | 15/70 (21.4%) | 60/70 (85.7%) |
| Event | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin | Post Crossover Tislelizumab |
|---|---|---|---|
| Platelet count decreasedInvestigations | 9/133 | 14/130 | 0/70 |
| Neutrophil count decreasedInvestigations | 3/133 | 6/130 | 0/70 |
| AnaemiaBlood and lymphatic system disorders | 3/133 | 5/130 | 1/70 |
| White blood cell count decreasedInvestigations | 3/133 | 5/130 | 0/70 |
| LeukopeniaBlood and lymphatic system disorders | 0/133 | 4/130 | 0/70 |
| PneumoniaInfections and infestations | 2/133 | 4/130 | 1/70 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/133 | 3/130 | 0/70 |
| SepsisInfections and infestations | 4/133 | 0/130 | 0/70 |
| Cerebral infarctionNervous system disorders | 0/133 | 1/130 | 2/70 |
| NeutropeniaBlood and lymphatic system disorders | 1/133 | 2/130 | 0/70 |
| Event | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin | Post Crossover Tislelizumab |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 114/133 | 117/130 | 19/70 |
| NauseaGastrointestinal disorders | 78/133 | 94/130 | 6/70 |
| White blood cell count decreasedInvestigations | 81/133 | 81/130 | 8/70 |
| Neutrophil count decreasedInvestigations | 80/133 | 76/130 | 6/70 |
| Platelet count decreasedInvestigations | 68/133 | 76/130 | 1/70 |
| VomitingGastrointestinal disorders | 55/133 | 68/130 | 4/70 |
| Decreased appetiteMetabolism and nutrition disorders | 64/133 | 65/130 | 4/70 |
| ConstipationGastrointestinal disorders | 46/133 | 60/130 | 11/70 |
| LeukopeniaBlood and lymphatic system disorders | 46/133 | 44/130 | 2/70 |
| NeutropeniaBlood and lymphatic system disorders | 46/133 | 38/130 | 1/70 |
The Intent to Treat (ITT) analysis set included all participants randomized to the study.
| Age, Continuous(years) | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Mean | 49.0 ± 10.62 | 49.5 ± 10.76 | 49.3 ± 10.67 |
| Sex: Female, Male(Participants) | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Female | 28 | 29 | 57 |
| Male | 103 | 103 | 206 |
| Race and Ethnicity Not Collected(Participants) | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| China | 122 | 126 | 248 |
| Thailand | 5 | 1 | 6 |
| Taiwan | 4 | 5 | 9 |
| Baseline Target Lesions Sum of Diameters Assessed by Investigator (mm)(Millimeters (mm)) | Arm A: Tislelizumab + Gemcitabine + Cisplatin | Arm B: Placebo + Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Mean | 65.49 ± 49.004 | 57.56 ± 40.389 | 61.51 ± 44.978 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Mar 2019 to primary completion in Mar 2021, 23 months.
Results were first posted in Jan 2025, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab